Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants
| Autoři | |
|---|---|
| Rok publikování | 2016 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | EXPERT OPINION ON PHARMACOTHERAPY |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | http://www.tandfonline.com/doi/full/10.1080/14656566.2016.1219340?scroll=top&needAccess=true |
| Doi | http://dx.doi.org/10.1080/14656566.2016.1219340 |
| Obor | Farmakologie a lékárnická chemie |
| Klíčová slova | Depressive disorder; pharmacoresistance; multimodal; multifunctional antidepressants; pharmacogenomic tests |
| Popis | Major depressive disorder (MDD) is a widespread disease, with a lifetime prevalence of 15% and an annual incidence of approximately 7%. It is associated with significant costs in quality of life, loss of work productivity, and a high risk of mortality. It is predicted to become the leading cause of disability in Western countries by 2030. |
| Související projekty: |